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Highly sensitive colorimetric detection of allergies
based on an immunoassay using peroxidase-
mimicking nanozymes†
Seongyeon Cho,‡a Sang Min Lee,‡b Ho Yun Shin,a Min Su Kim,c Yiel Hea Seo,d
Yong Kyun Cho,e Jinwoo Lee, c Sang Pyo Lee*b and Moon Il Kim *a
Nanomaterials that exhibit enzyme-like characteristics, which are called nanozymes, have recently
attracted signiﬁcant attention due to their potential to overcome the intrinsic limitations of natural
enzymes, such as low stability and relatively high cost for preparation and puriﬁcation. In this study, we
report a highly eﬃcient colorimetric allergy detection system based on an immunoassay utilizing the per-
oxidase-mimicking activity of hierarchically structured platinum nanoparticles (H-Pt NPs). The H-Pt NPs
had a diameter of 30 nm, and were synthesized by a seed-mediated growth method, which led to a sig-
niﬁcant amount of peroxidase-like activity. This activity mainly occurs because of the high catalytic power
of the Pt element, and the fact that the H-Pt NPs have a large surface area available for catalytic events.
The H-Pt NPs were conjugated to an antibody for the detection of immunoglobulin E (IgE) in the analytes;
IgE is a representative marker for the diagnosis of allergies. They were then successfully integrated into a
conventionally used allergy diagnostic test, the ImmunoCAP diagnostic test, as a replacement for natural
signaling enzymes. Using this strategy, total and speciﬁc IgE levels were detected within 5 min at room
temperature, with high speciﬁcity and sensitivity. The practical utility of the immunoassay was also
successfully veriﬁed by correctly determining the levels of both total and speciﬁc IgE in real human serum
samples with high precision and reproducibility. The present H-Pt NP-based immunoassay system would
serve as a platform for rapid, robust, and convenient analysis of IgE, and can be extended to the construc-
tion of diagnostic systems for a variety of clinically important target molecules.
1. Introduction
An allergy indicates a disorder of hypersensitivity, in which the
immune system reacts to normally harmless substances,
which are called allergens. A variety of allergens can enter the
human body via inhalation or ingestion, and cause allergic
reactions of the respiratory tract, skin, and gastrointestinal
organs. These reactions could induce diverse adverse symp-
toms, such as eye redness, itchiness, rhinorrhea, eczema,
abdominal cramping, and dyspnea.1
To identify causal allergens, the skin prick test was
traditionally used for patients with allergies; however, this
method has some limitations such as inconvenience to
patients, interruption by anti-histamine medications, false
positivity due to dermographism, and low reliability while eval-
uating food allergens.2 To overcome and compensate for these
limitations, direct measurement of the serum level of allergen-
specific IgE is frequently performed. For determination of IgE
levels, several immunological methods have been developed,
including the radioallergosorbent test (RAST), liquid-phase
enzyme immunoassay, enzyme-linked immunosorbent assay
(ELISA), or fluorescent enzyme immunoassay (FEIA).3–11 The
assays generally involve a single allergen or total allergen-
specific immunoreaction; they yield sensitive, precise, and
quantitative results for measuring total or allergen-specific IgE
levels in the serum. Among them, the commercially available
ImmunoCAP (Phadia, Uppsala, Sweden), which is based on
ELISA performed in the solid-phase, is considered as a gold
standard for the diagnosis of allergy.5 The ImmunoCAP test
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employs a polymeric cellulose membrane, which enables a
high binding capacity of allergens on it, consequently resulting
in enhanced sensitivity to determine the target IgE molecules.
This technology, which provides quantitative measurements of
the IgE levels in blood, has also been approved by the Food
and Drug Administration (FDA).12,13 Although this method
enables the selective and sensitive detection of the target IgE
molecules, its performance is limited due to the inevitable
drawbacks of using natural enzymes, including their intrinsic
instability during long-term operation or storage, and relatively
high costs involved in their preparation and purification.
To overcome these limitations, we herein developed an
eﬃcient colorimetric assay system, based on enzyme-mimick-
ing nanomaterials (nanozymes).14–16 Diverse kinds of nano-
zymes, which show a considerable amount of enzyme-like
activity with high stability, have been reported and applied to
the development of colorimetric immunoassay systems.17–19
Among them, Pt-based nanozymes have attracted exceptional
interest due to their super catalytic activity to oxidize a chro-
mogenic substrate into a colored product.20–25 To maximize
the peroxidase-like activity of Pt-based nanozymes, we also
recently reported hierarchically structured Pt nanoparticles
(H-Pt NPs) that show superior peroxidase-like activity under
operating conditions because of their extremely large surface
area that could be used for catalytic events.26 The H-Pt NPs,
conjugated to antibodies against total or specific IgE, were
found to exhibit excellent selectivity for the target IgE when
used in the ImmunoCAP test, as a replacement for enzyme–
antibody conjugates. Moreover, by employing the new method,
the levels of the target IgE molecules can be conveniently
determined by simply measuring the intensity of blue color
generated by the H-Pt NP-mediated colorimetric reaction of
the applied peroxidase substrate, 3,3′,5,5′-tetramethyl-
benzidine (TMB) with H2O2. The clinical utility for determin-
ing diverse levels of both total and specific IgE present in real
human blood serum samples was also evaluated.
2. Materials and methods
2.1 Materials
Chloroplatinic acid hexahydrate (H2PtCl6·6H2O), sodium boro-
hydride (NaBH4), sodium citrate, citric acid, horseradish per-
oxidase (HRP), 3,3′,5,5′-tetramethylbenzidine (TMB), bovine
serum albumin (BSA), human serum albumin (HSA), and
glucose were purchased from Sigma-Aldrich (Milwaukee, WI),
and 35% hydrogen peroxidase (H2O2) solution was purchased
from Junsei Chemical Co. (Japan). All chemicals were of
analytical grade, and used without further purification. All
solutions were prepared with double distilled water purified by
a Milli-Q purification system (Millipore).
2.2 Synthesis of H-Pt NPs
H-Pt NPs were prepared according to our previously reported
seed-mediated growth method in aqueous solution.27 Pt nano-
particle seeds were first prepared through the reduction of
chloroplatinic acid using sodium borohydride. In the reaction,
9 mL of 0.2% chloroplatinic acid solution was added to
116 mL of boiling deionized (DI) water, and incubated for
1 min. Then, 2.75 mL of 1% sodium citrate–0.05% citric acid
solution was added, followed by a 1 min incubation period.
Then, 1.38 mL of an aqueous solution containing 0.08%
sodium borohydride and 1% sodium citrate–0.05% citric acid
was added into the reaction mixture. After incubation for
10 min, the mixture was cooled to room temperature (RT) to
produce a seeding solution. The seeding solution (10 mL) was
diluted with 90 mL of DI water, followed by the addition of
0.5 mL of 0.4 M chloroplatinic acid solution and 5 mL of 1%
sodium citrate–1.25% L-ascorbic acid solution. The resulting
solution was heated to its boiling point, incubated for 30 min,
and then cooled to RT. Finally, the H-Pt NPs were purified by
thoroughly washing them thrice with DI water. The morpho-
logy of the H-Pt NPs was examined using scanning electron
microscopy (SEM) with an S-4200 field-emission SEM
(Hitachi), transmission electron microscopy (TEM) with a JEOL
JEM-2200FS, and dynamic light scattering (DLS) with a
Malvern Nano-ZS.
2.3 Determination of peroxidase activity and stability
To investigate the peroxidase-like activity of the H-Pt NPs, the
catalytic oxidation of TMB in the presence of pre-determined
concentrations of H2O2 was performed in a transparent 96-well
plate as follows: a solution containing diverse kinds of nano-
materials including H-Pt NPs (20 μL, 0.1 mg mL−1), the TMB
substrate (20 μL, 0.5 mM), and H2O2 (20 μL, 100 mM) in a
sodium acetate buﬀer (140 μL, 0.2 M, pH 4.0) was added into
each well and incubated at RT for 3 min. After the
reaction, the well-plate was used to capture color images.
Spectrophotometric measurements were carried out in a scan-
ning mode, or at 652 nm using a microplate reader (Synergy
H1, BioTek, VT), after separating the nanomaterials from the
mixtures in each well by centrifugation at 10 000g for 3 min.
The stability of the H-Pt NPs and HRP was evaluated in
sodium acetate buﬀer (0.2 M, pH 4.0) and sodium phosphate
buﬀer (0.2 M, pH 6.0), respectively, under static conditions at
RT. First, the initial activity was determined. Subsequently, the
residual activity of each sample was determined by measuring
the absorbance at 652 nm as described above. The relative
activity (%) was calculated by obtaining the ratio of the
residual activity to the initial activity of each sample.
2.4 Preparation of antibody-conjugated H-Pt NPs
Antibody conjugated H-Pt NPs (Ab-H-Pt NPs) were prepared by
facilitating the adsorption of the antibodies onto the surface
of the H-Pt NPs. Antibodies against IgE (anti-IgE, Abcam) were
used for conjugation. Briefly, 250 μL of H-Pt NPs (1.0 mg mL−1)
in DI water and 250 μL of anti-IgE (200 μg mL−1) were mixed,
and 500 μL of storage buﬀer (PBS solution (pH 7.4) containing
0.1% Tween-20 and 3% BSA) was added to the mixture to
block nonspecific binding sites. The Ab-H-Pt NPs were incu-
bated for 1 day at 4 °C with gentle shaking, then washed thrice
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with PBS buﬀer and stored at 4 °C with their final concen-
tration being 0.1 mg mL−1.
2.5 H-Pt NP-based immunoassay to detect IgE on the
ImmunoCAP system
For the determination of total IgE, each ImmunoCAP, which
contained the antibody toward total IgE (anti-IgE) on its mem-
brane, was inserted into each well of the 96-well plate, and
200 μL of washing buﬀer prepared as per the manufacturer’s
instructions was added to each well and incubated for 30 min
to remove the coating of ImmunoCAP. After the plates were
washed with the PBS solution, 200 μL of sample solutions con-
taining human IgE were added to the ImmunoCAP-inserted
wells and incubated for 1 h at RT to allow the antigen–anti-
body interaction. The reacted ImmunoCAP was then washed
several times and further incubated with 200 μL of Ab-H-Pt
NPs (0.1 mg mL−1) for 2 h at RT. After thorough washings with
the PBS solution, a color development reaction was carried out
using 250 μL of development solution containing 0.5 mM TMB
as the chromogen, with H2O2 (100 mM) in PBS solution
(pH 4.0). After 5 min, the color-generating reaction was
immediately stopped by removing the ImmunoCAP and trans-
ferring the reacted solution into a new 96-well plate; this was
used to capture color images. Spectrophotometric measure-
ments were carried out at 652 nm using a microplate reader
(Synergy H1, BioTek, VT). For the determination of specific
IgE, ImmunoCAPs containing the specific allergen on their
membrane were used instead of ImmunoCAPs containing anti-
IgE; the other procedures were performed as described
previously.
In the experiments of HRP-based immunoassay to detect
IgE on the ImmunoCAP system, an HRP-conjugated mono-
clonal antibody against human IgE from mice (0.2 mg mL−1)
was employed instead of Ab-H-Pt NPs, and the development
solution containing 2 mM H2O2 was used instead of 100 mM
H2O2. The other procedures were the same as those used for
the immunoassay using the H-Pt NPs.
Diagnoses of allergies by determining the total or specific
IgE levels using the H-Pt NP-based immunoassay were carried
out with real blood serum samples, which were collected from
local hospitals. Clinical serum specimens were prepared by
centrifuging blood samples at 2000g for 10 min at 4 °C, fol-
lowed by the collection of the supernatant. The collected
serum samples were stored at −80 °C until use. The actual con-
centrations of IgE in clinical blood serum samples were deter-
mined by standard ImmunoCAP procedures using Phadia 250
instrumentation (Thermo Scientific). To assess the reliability
and reproducibility of this method for the determination of
total and several specific IgE levels, three parallel assay experi-
ments were performed, and their within-assay variation
was determined. The recovery rate [recovery (%) = measured
value/actual value × 100] and coeﬃcient of variation [CV (%) =
SD/average × 100] were determined to evaluate the precision
and reproducibility of the assays.
3. Results and discussion
3.1 Construction of H-Pt NPs for colorimetric determination
of IgE
As an eﬀective nanozyme to replace the signaling enzyme,
β-galactosidase, in the ImmunoCAP diagnostic system, H-Pt
NPs, which were proven to exhibit a great ability for catalyzing
redox reactions due to the high catalytic power of the Pt
element and their large surface area, were synthesized follow-
ing previous reports.26,27 The synthesized H-Pt NPs were
monodispersed with a narrow size distribution of a diameter
of ∼30 nm, and had rough, porous, and extremely large sur-
faces, which can be utilized for the catalytic events (Fig. 1).
Relevant antibodies against human IgE were subsequently con-
jugated to the surface of H-Pt NPs via a simple physical
adsorption method. These Ab-H-Pt NPs bind to the target
human IgE in a sample via a mechanism similar to that of the
sandwich-type immunoassay. Finally, when H2O2 and the
selected peroxidase substrate, TMB, are applied, the H-Pt NPs
catalyze the quick oxidation of TMB to generate a blue-colored
product (Fig. 2).
3.2 Investigation of the peroxidase-like activity of H-Pt NPs
We first examined the peroxidase activity of H-Pt NPs by per-
forming the representative peroxidase-catalyzed TMB oxidation
reactions in the presence of H2O2, while monitoring the
responses by using absorption spectroscopy (Fig. 3). The
results of this experiment show that the H-Pt NPs exhibit
much more intense TMB oxidation rates than the other nano-
zyme systems that we have previously developed, such as bare
Pt NPs, bare Fe3O4 magnetic nanoparticles (MNPs), amino-
propyl-triethoxysilane-modified MNPs (APTES-MNPs), meso-
porous silica particles entrapping 40 wt% MNPs (MSU_40%),
and graphene oxide (GO).28–31 The extremely high peroxidase
activity of H-Pt NPs was also previously demonstrated through
its comparison with the activity of horseradish peroxidase
Fig. 1 Characterization of H-Pt NPs. (a) SEM and (b, c) TEM images of
H-Pt NPs, and (d) hydrodynamic size distribution of H-Pt NPs by DLS.
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(HRP), an enzyme that is widely used in immunoassays for
signal amplification.26 Observations made in studies on the
eﬀects of the initial concentrations of TMB, H2O2, and reaction
time on the catalytic activity of H-Pt NPs showed that 0.5 mM
TMB, 100 mM H2O2, and 5 min reaction time were the ideal
assay conditions which were employed in further analyses
(Fig. S1†). H-Pt NPs were also highly stable over a long incu-
bation period at RT, whereas the HRP lost all of its activity
within 1 day of incubation. This demonstrates the robust
nature of H-Pt NPs, which facilitates their practical applica-
bility (Fig. 4).
3.3 Colorimetric determination of IgE using an H-Pt NP-
based ImmunoCAP assay system
The feasibility of the peroxidase-mimicking nanozyme, H-Pt
NPs, to detect IgE was demonstrated by integrating them into
the ImmunoCAP assay system, as a replacement for the natural
signaling enzyme. The ImmunoCAP system was generally pre-
pared by using β-galactosidase conjugated to antibodies
against human IgE, to assess the binding of IgE with specific
allergens on the membrane of the ImmunoCAP. However, the
intrinsic instability of β-galactosidase, which depends on the
various environmental parameters including temperature, pH,
and storage time, frequently produces false positive results,
and limits its utilization during long-term operation or
storage. The aforementioned unique superiorities of H-Pt NPs,
including their high activity and stability, led us to hypothesize
that they can eﬃciently replace β-galactosidase in the
ImmunoCAP-based allergy detection system. In addition, the
conventional ImmunoCAP assay based on β-galactosidase
needs special instrumentation for the identification of fluo-
rescent responses, while H-Pt NPs can oxidize versatile chro-
mogenic substrates such as TMB, in the presence of H2O2,
making the reaction procedures much more simple and con-
venient due to the ability of visual discrimination. Overall, we
expect that this H-Pt NP-based ImmunoCAP diagnostic assay
for allergies would enable convenient, reliable, and sensitive
quantification of the target IgE at a lower cost in comparison
with the conventional natural enzyme-based ImmunoCAP
system.
Through the immunoassay procedures described in the
Materials and methods section, H-Pt NPs conjugated to
specific antibodies against total IgE or specific IgE were
applied to the ImmunoCAP system using standard IgE
samples, which were provided by manufacturers. Although
various surface coatings on nanozymes have been reported to
bring about a significantly reduced catalytic activity,17–19 the
current antibody conjugation protocol produces nanoparticles
retaining greater than 80% of the original activity (Fig. S2†).
We first performed an experiment to evaluate the specificity of
the H-Pt NP-based assay to detect the target IgE. As shown in
Fig. 5a and b, significant absorption intensities corresponding
to the oxidized TMB were rapidly (within 5 min at RT)
observed in the wells containing the target IgE molecules,
whereas the wells containing negative control samples did not
produce significant color changes. This confirms the specific
binding of the Ab-H-Pt NPs to the target IgE molecules present
on the membrane of the ImmunoCAP system. When the con-
centrations of both total IgE and specific IgE increased, the
Fig. 2 Schematic illustration of the (a) conventional and (b) peroxidase-
mimicking H-Pt NP-based ImmunoCAP diagnostic systems for the
quantiﬁcation of human IgE.
Fig. 3 (a) Absorption spectra and (b) their corresponding images from
the representative color-generating reaction of TMB in the presence of
H2O2 using diverse nanozymes, including H-Pt NPs. (b) Time-dependent
absorbance changes at 652 nm in the presence of the nanozymes.
Fig. 4 Catalytic stabilities of the H-Pt NPs and HRP against incubation
time at RT. The error bars represent the standard deviations derived
from three independent measurements.
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intensity of the blue color signal, corresponding to the oxi-
dized TMB substrate, correspondingly increased, which was
also detected by the naked eye alone (Fig. 5c and d). Most
importantly, by the color signal development for 5 min, the
level of the absorption intensity produced by the H-Pt NPs was
higher than that produced by the HRP used in the convention-
al ELISA system; additionally, our H-Pt NP-based system was
able to quantify the target IgE very rapidly within 5 min,
whereas the conventional ELISA usually requires several tens
of minutes for color signal development.32 Based on the linear
calibration plot, the limit of detection (LOD) for total IgE was
determined to be as low as 0.25 kU L−1 in the dynamic linear
range from 0.4 to 1000 kU L−1 (Fig. 6a). For specific-IgE, the
LOD was determined to be as low as 0.17 kU L−1 in the linear
range from 0.35 kU L−1 to 17.5 kU L−1 (Fig. 6b). These LOD
and linear range values, which are associated with describing
the immunological determination of human IgE, are among
the best results obtained so far (Table S1†).33,34
3.4 Determination of IgE using clinical blood samples
Finally, we evaluated the actual diagnostic ability of the H-Pt
NP-based ImmunoCAP assay system by using real human
blood samples that contain diverse levels of total IgE or four
kinds of specific IgEs corresponding to d1 (Dermatophagoides
pteronyssinus), d2 (Dermatophagoides farinae), e1 (cat dander),
and e5 (dog dander). The actual levels of total or specific IgE
in the serum samples were first determined by standard
ImmunoCAP procedures using Phadia 250 instrumentation
(Thermo Scientific). As a result, total and specific IgE levels
were quantified with excellent precision, yielding CVs in the
range of 3.6–8.3% and 2.3–8.3%, with recovery rates varying
from 95.4 to 101.3% and from 95.5 to 102.9%, respectively
(Tables 1 & 2), verifying the excellent reproducibility and
reliability of the method. The results demonstrate that the
H-Pt NP-based ImmunoCAP assay system for the determi-
nation of IgE could be a promising analytical platform capable
of diagnosing allergies in clinical settings.
Fig. 5 Absorption intensities of well plates for the H-Pt NP-based
ImmunoCAP assay to speciﬁcally detect (a) total IgE and (b) speciﬁc IgE,
and absorption intensities of the blue color signal and their corres-
ponding images for the immunoassay to detect (c) total IgE and (d)
speciﬁc IgE at various concentrations by using H-Pt NPs and HRP. For
(a) and (b), the employed concentrations of total and speciﬁc IgE are
2.42 μg mL−1 (1000 kU L−1) and 0.242 μg mL−1 (100 kU L−1), respectively,
while those for negative control samples are all 10 μg mL−1. The error
bars represent the standard deviation derived from three independent
measurements.
Fig. 6 Linear calibration plots of the H-Pt NP-based ImmunoCAP assay
system for the quantiﬁcation of (a) total IgE and (b) speciﬁc IgE.
Table 1 Detection precision for H-Pt NP-based total IgE detection
from real clinical serum samples
Sample no.
Expected
(kU L−1) Average SD CV (%)
Recovery
(%)
1 496 483.2 37.70 7.8 97.4
2 471 471.5 30.63 6.4 100.1
3 920 896.4 32.99 3.6 97.4
4 125 126.6 9.43 7.4 101.3
5 351 339.9 28.28 8.3 96.8
6 430 421.5 16.49 3.9 98.0
7 415 406.5 18.45 4.6 97.0
8 117 111.6 7.07 6.3 95.4
9 68.4 66.6 4.71 7.1 97.4
10 194 186.6 9.43 5.1 96.2
Table 2 Detection precision for H-Pt NP-based speciﬁc IgE detection
from real clinical serum samples
Sample
no. Allergen
Expected
(kU L−1) Average SD
CV
(%)
Recovery
(%)
1 e5 59.5 60.5 1.66 2.7 101.7
2 d1 4.08 4.1 0.26 6.4 100.5
d2 9.96 9.7 0.70 7.2 97.4
3 d1 29.9 29.5 1.79 6.1 98.7
d2 26.0 26.2 1.32 5.0 100.8
e1 >100 118.4 6.22 5.3 N.D.
e5 7.78 8.0 0.30 3.8 102.8
4 d1 20.6 21.2 1.47 6.9 102.9
d2 16.6 16.8 0.66 3.9 101.2
e5 38.2 36.5 3.04 8.3 95.5
5 d1 25.1 25.4 1.14 4.5 101.2
d2 62.1 60.8 1.37 2.3 97.9
d1: Dermatophagoides pteronyssinus, d2: Dermatophagoides farinae, e1:
cat dander, e5: dog dander, and N.D. indicates “not determined”.
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4. Conclusion
We herein developed an eﬃcient colorimetric immunoassay
for detecting and determining the concentration of IgE based
on the high peroxidase activity of H-Pt NPs. The results of this
investigation demonstrate that the H-Pt NP-based ImmunoCAP
assay system has high sensitivity, stability, and precision for
the detection of the corresponding IgE. Since the current
system enabled the rapid visual detection of the target IgE, it
should find practical applications in facility-limited or point-
of-care testing environments, without the addition of natural
enzymes. Because the H-Pt NPs can rival natural signal
enzymes due to their high activity, stability, robustness, and
low cost by a facile scale-up, the analytical platform can be
further extended to many potential applications as a con-
venient diagnostic tool for clinical analysis.
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